Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis

Objective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently...

Full description

Bibliographic Details
Main Authors: Kaleb Michaud, Bernard Vrijens, Eric Tousset, Sofia Pedro, Rebecca Schumacher, Gorana Dasic, Connie Chen, Ekta Agarwal, Maria E. Suarez‐Almazor
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11079
id doaj-077270b7f0664a2bb3a7d4f9334eb12c
record_format Article
spelling doaj-077270b7f0664a2bb3a7d4f9334eb12c2020-11-25T02:03:01ZengWileyACR Open Rheumatology2578-57452019-11-011956057010.1002/acr2.11079Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid ArthritisKaleb Michaud0Bernard Vrijens1Eric Tousset2Sofia Pedro3Rebecca Schumacher4Gorana Dasic5Connie Chen6Ekta Agarwal7Maria E. Suarez‐Almazor8University of Nebraska Medical Center, Omaha, Nebraska and Forward, The National Databank for Rheumatic Diseases Wichita KansasAARDEX Group, Visé, Belgium, and University of Liège Liège BelgiumAARDEX Group Visé BelgiumForward, The National Databank for Rheumatic Diseases Wichita KansasForward, The National Databank for Rheumatic Diseases Wichita KansasPfizer Inc. New York New YorkPfizer Inc. New York New YorkPfizer Inc. New York New YorkUniversity of Texas MD Anderson Cancer Center HoustonObjective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently (12 months or sooner) initiated oral MTX. MEMS was used to compile MTX weekly dosing over 24 weeks. The Beliefs about Medicines Questionnaire (BMQ) was completed, and baseline demographics and disease characteristics obtained. MTX adherence (percentage of weeks dose taken correctly), implementation (percentage of weeks dose taken correctly from initiation until last dose), and persistence (duration from initiation to last dose) were calculated. Analyses measured associations between patient characteristics and adherence, modeled using logistic generalized estimating equations and censored Poisson regression, and persistence modeled using Cox regression. Results Overall, 60 of 119 eligible patients were included in the analysis. MTX adherence, implementation, and persistence were 75%, 80%, and 83%, respectively, at 24 weeks. Demographics and disease characteristics were generally similar between patients with 1 week or less and 2 weeks or more of missed MTX. Unemployment, less disability, higher Patient Global scores, and no prior disease‐modifying antirheumatic drug (DMARD) use were associated with correct dosing. No significant differences in adherence were observed between patients receiving concomitant MTX versus MTX monotherapy, and biologic DMARD‐experienced versus biologic DMARD‐naïve patients. Higher scores in BMQ Specific Necessity (indicating a greater belief in the necessity of the medication) was associated with a decreased likelihood of dosing at an interval shorter than prescribed (odds ratio 0.89). Conclusion Even in a participatory group over a short period, MTX adherence was suboptimal and associated with certain demographics, medication experience, and beliefs about medicines. This suggests a need for screening and alternative treatment opportunities in nonadherent MTX patients with RA.https://doi.org/10.1002/acr2.11079
collection DOAJ
language English
format Article
sources DOAJ
author Kaleb Michaud
Bernard Vrijens
Eric Tousset
Sofia Pedro
Rebecca Schumacher
Gorana Dasic
Connie Chen
Ekta Agarwal
Maria E. Suarez‐Almazor
spellingShingle Kaleb Michaud
Bernard Vrijens
Eric Tousset
Sofia Pedro
Rebecca Schumacher
Gorana Dasic
Connie Chen
Ekta Agarwal
Maria E. Suarez‐Almazor
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
ACR Open Rheumatology
author_facet Kaleb Michaud
Bernard Vrijens
Eric Tousset
Sofia Pedro
Rebecca Schumacher
Gorana Dasic
Connie Chen
Ekta Agarwal
Maria E. Suarez‐Almazor
author_sort Kaleb Michaud
title Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
title_short Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
title_full Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
title_fullStr Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
title_full_unstemmed Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
title_sort real‐world adherence to oral methotrexate measured electronically in patients with established rheumatoid arthritis
publisher Wiley
series ACR Open Rheumatology
issn 2578-5745
publishDate 2019-11-01
description Objective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently (12 months or sooner) initiated oral MTX. MEMS was used to compile MTX weekly dosing over 24 weeks. The Beliefs about Medicines Questionnaire (BMQ) was completed, and baseline demographics and disease characteristics obtained. MTX adherence (percentage of weeks dose taken correctly), implementation (percentage of weeks dose taken correctly from initiation until last dose), and persistence (duration from initiation to last dose) were calculated. Analyses measured associations between patient characteristics and adherence, modeled using logistic generalized estimating equations and censored Poisson regression, and persistence modeled using Cox regression. Results Overall, 60 of 119 eligible patients were included in the analysis. MTX adherence, implementation, and persistence were 75%, 80%, and 83%, respectively, at 24 weeks. Demographics and disease characteristics were generally similar between patients with 1 week or less and 2 weeks or more of missed MTX. Unemployment, less disability, higher Patient Global scores, and no prior disease‐modifying antirheumatic drug (DMARD) use were associated with correct dosing. No significant differences in adherence were observed between patients receiving concomitant MTX versus MTX monotherapy, and biologic DMARD‐experienced versus biologic DMARD‐naïve patients. Higher scores in BMQ Specific Necessity (indicating a greater belief in the necessity of the medication) was associated with a decreased likelihood of dosing at an interval shorter than prescribed (odds ratio 0.89). Conclusion Even in a participatory group over a short period, MTX adherence was suboptimal and associated with certain demographics, medication experience, and beliefs about medicines. This suggests a need for screening and alternative treatment opportunities in nonadherent MTX patients with RA.
url https://doi.org/10.1002/acr2.11079
work_keys_str_mv AT kalebmichaud realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT bernardvrijens realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT erictousset realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT sofiapedro realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT rebeccaschumacher realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT goranadasic realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT conniechen realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT ektaagarwal realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
AT mariaesuarezalmazor realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis
_version_ 1724949920133152768